Big Pharma players are likely to be most successful at turning out generic versions of biotech drugs, or biosimilars, because major drugmakers have the necessary marketing muscle and development expertise, Reuters reports. Report
The hunt for proof-of-concept data is steadily moving upstream in the clinic. Join FierceBiotech on June 12th as three clinical trial experts tackle the question of how you can best design a Phase I study to get a readout on efficacy. Topics will include: enrollment, dosing and the best possible use of biomarkers for experimental cancer drugs. Register Today!
Comments